Overview

Phase II Study of Carfilzomib, Pomalidomide, and Dexamethasone for Myeloma Patients Who Had Relapsed or Progressed After Carfilzomib, Lenalidomide, and Dexamethasone

Status:
Recruiting

Trial end date:
2024-06-30

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the evaluate the efficacy and safety of administering a combination of carfilzomib, pomalidomide, and dexamethasone in patients with relapsed or advanced multiple myeloma after carfilzomib, lenalidomide, and dexamethasone therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Samsung Medical Center

Treatments:

Dexamethasone
Pomalidomide